Finnish Scientists Identify Link Between GlaxoSmithKline’s Swine Flu Vaccine Pandemrix and Narcolepsy

By Amirah Al Idrus
Global Research, January 06, 2015
FierceVaccines 17 December 2014
Theme:

Of the more than 30 million people in almost 50 countries who have received GlaxoSmithKline’s ($GSK) Pandemrix, close to 800 have developed narcolepsy. And now, for the first time, a team from Finland thinks it knows why.

Comparing Pandemrix with Arepanrix, a vaccine used in Canada with the same adjuvant, the researchers found that Pandemrix had more of one structurally altered viral nucleoprotein–a disparity lead researcher Outi Vaarala attributed to the way the vaccines were prepared.

“The vaccine virus itself has components of the virus. It is also supposed to contain viral protein. There’s nothing extraordinary about that,” she told Yle, Finland’s national broadcasting company. “The difference was that Pandemrix had one viral protein in a different form and there was more of it.”

In February 2011, Finland’s National Institute for Health and Welfare announced a spike in narcolepsy cases and a link between Pandemrix and the sleep disorder. Recipients of the vaccine aged between four and 19 had a “manifold” increased risk of developing narcolepsy during the 8 months following vaccination, as compared with those of the same age group who had foregone the vaccine, said the health agency.

In May 2013, researchers in Finland found that it wasn’t only kids who were susceptible to narcolepsy after getting Pandemrix, but adults, too, though the findings suggested that the risk of developing narcolepsy tapers off with age.

And in September 2013, the U.K. government, which had previously turned down compensation claims for Pandemrix-related narcolepsy, changed its mind 7 months after new evidence came to light. Research published in the British Medical Journal showed an increased risk of narcolepsy in English children who had received Pandemrix.

– here’s the study abstract
– get more from Yle
Articles by: Amirah Al Idrus

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]